Recce Ltd has released a press release.
Recce Pharmaceuticals: Half Yearly Report and Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Positive Efficacy Data in Kidney/UTI infections animal model
- Positive Data from RECCE 327 Antibiotic Safety Studies
- Appendix 4C and Commentary
- Positive Data for RECCE 327 in MRSA Burns Wound Infection
- Recce Completes Raising of $6.76 million
Later from Recce Pharmaceuticals
- First-in-Human Clinical Trial Progress Update
- Recce Signs Phase I Human Clinical Trial Agreement
- Positive Data on RECCE 327 Against Influenza A
- Further Positive Data on RECCE 327 Against MRSA Superbug
- Positive Data on RECCE 327 Against Neisseria gonorrhoeae
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals